Pharmos

[Ca$hmandt]

Hohes volumen und gegen den trend nach oben, insbesondere im letzten drittel des handelstages. Morgen (24.06) könnten interessante news kommen, die auf der bio-konferenz bekanntgegeben werden:

Pharmos Corporation to Present at the BIO 2003 Annual Convention Business Forum

Pharmos Also Participating in Panel on Development of Therapies for Neurological Disorders

ISELIN, N.J., June 20 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS; Nasdaq Europe: PHRM) announced today Dr. Gad Riesenfeld, President & COO, will present at the Business Forum of the BIO 2003 Annual Convention in Washington D.C. on Tuesday, June 24, at 2:15 p.m. Eastern Time. Pharmos' presentation will concentrate on dexanabinol, the Company's lead compound under development, currently being tested clinically for traumatic brain injury (Phase III trial) and mild cognitive impairment in cardiac surgery patients (Phase IIa). The presentation will also outline some of the promising earlier stage compounds from the Company's rich neurological pipeline.

Organizers from the Biotechnology Industry Organization (BIO) expect between 15,000 and 20,000 biotechnology executives, politicians, scientists, and reporters to attend from more than 50 different countries. A simultaneous webcast of Pharmos' Business Forum presentation will be available at http://www.firstcallevents.com/service/ajwz382704448gf12.html, and will be archived for a limited time after the conference.

Separately, Dr. Howard Grossberg, Pharmos R&D Medical Advisor, will participate in a panel discussion entitled "The Final Frontier: Therapies to Treat Neurological Disorders" at 2:15 p.m. Eastern Time on Monday, June 23. The panel will explore the nuances of brain research and drug development for debilitating disorders, including traumatic brain injury, mild cognitive impairment, Alzheimer's disease and Parkinson's disease. The panel will be chaired by Dr. Ross Stein, Director, Lab for Drug Discovery in Neurodegeneration, Harvard Center for Neurodegeneration and Repair. This event will not be webcast.

Pharmos discovers, develops, and commercializes novel therapeutics to treat a range of indications, in particular neurological and inflammation- based disorders. The Company's first neuroprotective product is dexanabinol, a tricyclic dextrocannabinoid, currently undergoing clinical testing as a treatment for TBI and as a preventive agent against post-surgical cognitive impairment. Other dextrocannabinoid compounds and CB2 receptor agonist compounds from Pharmos' proprietary synthetic cannabinoid library are being studied in pre-clinical programs targeting stroke, pain, multiple sclerosis and other disorders.

Statements made in this press release related to future beneficial expectations and projections of the Company are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties which may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.

ein produkt in phase III und eins in phase IIa.

[Big AL]

THX für die Info Cashi, PARS sieht schon heute nicht schlecht aus! :)

Ich werde mir die für einen Intraday-Ausbruch ins Alert-System legen...


Greets

Big AL

[Ca$hmandt]

man kann davon ausgehen, das die nachrichten positiv werden, BIOM wollte ja eigentlich auch auf der bio konferenz berichten, aber deren testergebnisse waren ja bekanntlich schlecht, so daß man es vorzog, sich nicht auf der konferenz zu blamieren....
nachbörslich nochmal 1,8 % nach oben....

hier noch ein chart:

[Ca$hmandt]

THX für die Info Cashi, PARS sieht schon heute nicht schlecht aus!

Ich werde mir die für einen Intraday-Ausbruch ins Alert-System legen...


manchmal finde sogar ich ein korn..... :D ;)

[siko®]

:D
http://www.aktienboard.com/vb/attachment.php?postid=633954

[the mind]

PARS sieht gut aus, danke Cashi! ;)

http://chart.bigcharts.com/bc3/intchart/frames/chart.asp?symb=pars&compidx=aaaaa%3A0&ma=1&maval=20%2C50%2C100%2C200&uf=0&lf=268435456&lf2=65536&lf3=1024&type=4&size=2&state=11&sid=3748&style=320&time=7&freq=1&comp=NO%5FSYMBOL%5FCHOSEN&nosettings=1&rand=6427&mocktick=1


vergiß nicht den flachmann zu verstecken, siko ist durstig! :D

http://www.die-bassisten.de/bilder/flachmann.gif

[Ca$hmandt]

momentan sehen sie aber nicht so doll aus...... :(

hier noch ein paar weitergehende infos für alle "nicht"chartler:

[Ca$hmandt]

!

[Ca$hmandt]

!!

[Ca$hmandt]

Louis Navellier stock newsletter's stock grader raised PARS overall rating based on 10 criteria to a B from a C recently.

More cash will be good for one or 2 of the criteria I bet.

I will check in coming days for a move to an A grade. Institutions will react positively to an A grade BioTech that's in the 2 dollar range. Getting in on the ground floor.

Only a year or so before very well positioned in the market to command a bigger multiple.

Billion dollar market cap here we come.

aus dem yahoo board

[Ca$hmandt]

scheinen einige mehr zu wissen, 100k zum ende gehandelt bringen den wert ins plus:

[Ca$hmandt]

up! :D

[Ca$hmandt]

wie passend mein letzter Beitrag, heute vorbörslich über 10% hoch!

Pharmos Initiates US Enrollment in Phase III Study of Dexanabinol For Traumatic Brain Injury

Drug Holds Promise to be First TBI Therapeutic Treatment

ISELIN, N.J., July 1 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS and Nasdaq Europe: PHRM) announced today that U.S. enrollment has commenced in its Phase III study of dexanabinol for traumatic brain injury (TBI), ongoing in over 60 international centers where more than 630 patients have been enrolled to date. A total of up to fifteen U.S. trauma centers are expected to be active in the pivotal study, in which total patient enrollment is expected to be completed around yearend. Positive data from the study could enable Pharmos to submit an NDA to the FDA requesting marketing approval in the U.S. as the first therapeutic treatment for TBI. The world market for the product is estimated at over $1 billion annually.

The first patient in the U.S. was enrolled at Penn State Milton S. Hershey Medical Center in Hershey, Pennsylvania. The trial at that location is under the direction of Principal Investigator Kevin Cockroft, M.D., assistant professor, Department of Neurosurgery, and Associate Investigator Jonas Sheehan, M.D., assistant professor, Department of Neurosurgery. Raj K. Narayan, M.D., Chairman of the American Brain Injury Consortium (ABIC), Chairman of the Department of Neurosurgery at University of Cincinnati and a member of the dexanabinol study safety committee said, "Neurosurgeons and their patients as well as all other emergency medical personnel are in serious need of an effective medication that can protect the brain from severe damage in injured patients and thereby improve neurological outcome. The principal investigators participating in this study are very enthusiastic about having a product available to treat this significant problem. The initiation of patient enrollment in this trial may also raise public awareness over the magnitude and devastating impact of brain injury, thereby lending a voice to what has been referred to as a silent epidemic."

The expansion of the study to the U.S. follows FDA authorization of Pharmos' Investigational New Drug application. All of the U.S. centers are following the same protocol used internationally and will comply with ABIC procedural guidelines in clinical head injury trials. "We are happy to join efforts with our U.S. colleagues in the development of a product that is needed all over the world," said Dr. Graham Michael Teasdale, Chairman of the European Brain Injury Consortium (EBIC).

Haim Aviv, Ph.D., Pharmos Chairman and CEO, said, "Our goal in this trial -- to prove a significant clinical benefit for TBI patients -- is backed by favorable Phase I and II clinical data and solid results from our extensive research into the unique mechanism of action displayed by this compound. If this drug is successful, it will be the only approved drug to treat this condition and will represent a substantial commercial opportunity for Pharmos."

[Odo]

wie passend mein letzter Beitrag, heute vorbörslich über 10% hoch!

:dis: :dunce: ;)
bei 50.000 Stück

[Odo]

und nu sind noch 2,9 % geblieben :rolleyes:

[Ca$hmandt]

naja, es wurde ja auch nur mit phase 3 eines vielversprechenden medikantes begonnen, was ja an sich keine große meldung ist!

[the mind]

yo, die meisten bios die premarket phase 1, 2 oder 3 anfangen/abschliessen gappen up und werde dann abverkauft....meistens kein guter tag um long zu gehen.

[Ca$hmandt]

das merkwürdige ist immer nur, das die fetten umsätze mit den dicken steigerungen immer zu beginn der sitzung gefahren werden, auch hier wurden heute kanpp 1/5 in der ersten stunde gehandelt, zu höheren kursen.

d.h. ein großteil der anleger ist mal wieder auf der loserseite....zumindest heute. :D

[Ca$hmandt]

!

[Odo]

@Cashi:

was du alles am Chart erkennst :eek: ;)

[Ca$hmandt]

Synthetic marijuana compound tested for brain injuries

By Deena Beasley

LOS ANGELES, July 1 (Reuters) - Pivotal-stage U.S. testing was launched this week to see whether a synthetic derivative of marijuana might be the first effective treatment for traumatic brain injury.

Pharmos Corp. (NasdaqSC:PARS - News), a drug developer based in Iselin, New Jersey, on Tuesday said it initiated U.S. enrollment in a Phase 3 trial of dexanabinol, a version of the active ingredient in cannibis that has been designed not to bind to receptors that stimulate the psychotropic effects seen with naturally-occurring cannabinoids like marijuana.

The compound is already being tested in 60 international trauma centers. Results from the 900-patient trial are expected by the fourth quarter of next year, according to Pharmos Chief Operative Officer Gad Riesenfeld.

"When you have ischemia in the brain -- caused by a car accident, a stroke, or other injury -- the result is inflammation, apoptosis and necrosis. Brain cells are eventually killed and some people will die," he said.

Pharmos says dexanabinol protects against neurological deterioration in three ways -- it is an anti-inflammatory compound that can slow the breakdown of the blood-brain barrier and cell death, it prevents the lethal massive influx of calcium ions into the cells of the injured brain, and it is an anti-oxidant, acting to protect the brain by scavenging free radicals that are formed when an injury is sustained.

"Neurosurgeons and their patients as well as all other emergency medical personnel are in serious need of an effective medication that can protect the brain from severe damage in injured patients and thereby improve neurological outcome," said Dr. Raj Narayan, chairman of the Department of Neurosurgery at University of Cincinnati.

About 52,000 Americans die each year from head injuries, while another 80,000 suffer long-term disability.

In an earlier Phase 2 trial -- U.S. regulators typically require an experimental drug to be tested in three stages -- dexanabinol was shown to reduce brain swelling and improve responses such as memory, while a trend toward improved outcomes was seen.
The Phase 3 trial seeks to prove that the compound -- injected once within six hours of injury -- results in better patient outcomes based on a scale that ranges from death to a resumption of normal life.

Patients eligible for the trial must fall in the mid- to upper range of a different designed to measure the severity of coma. They will be given standard care in addition to either dexanabinol or placebo.

In the United States, the drug could be a treatment for about 150,000 out of an estimated 1.5 million annual head injuries, Riesenfeld said.

Pharmos estimated the the worldwide market for the product could exceed $1 billion annually. The company's shares rose 7 cents, or 3.4 percent, to close at $21.3 on Nasdaq.

[Ca$hmandt]

heute war (ist) ein feiner tag!

bei 2-fach über schnitt liegenden volumen geht die aktie rund 12% aufwärts und das ohne news..... :)

[Big AL]

Langsam sollte man über deine Sperrung nachdenken, Ca$hi! :D

Erst pusht du RBAK und dann PARS... :hmpf: ;)


Greets

Big AL

[Ca$hmandt]

rbak hab ich nicht gepusht, von pars bin ich überzeugt!
ohne nmeldung gings heute auf 1,60 und nun wieder auf 1,95 wie kann das sein? :confused:

[Schneewittchen]

rbak hab ich nicht gepusht, von pars bin ich überzeugt! :hmpf: das sagt Morchel auch immer.......

[Ca$hmandt]

nun glaube ich das meine argumentation doch wohl ein wenig fundamentierter ist.

mal schauen was du so pushst in deinem neuen us thread...

[Odo]

ich sollte medx mal pushen :rolleyes:

[Ca$hmandt]

o, da musst du aber erst mal den richtigen einstiegskurs finden, also pass auf den unterstützenden gleitenden durchschnitt auf, der sich mit diversen ellitwaves unter der 90 tage unterstützung befindet.

UND NICHT VERGESSEN: Fundamentale daten bitte völlig ausser acht lassen! :D ;)

[Big AL]

@Ca$hi

Ist aber sehr auffällig, was deine Tips so machen! :D

[Ca$hmandt]

ja schon klar, bin in allen werten die ich vorstelle short! :D

du hast übrigens BIOM vergessen :D

ich weiss auch nicht was los ist :rolleyes:

[Ca$hmandt]

Gad Riesenfeld, PhD, Discusses Company Milestones and Industry Size in Exclusive www.Wallst.net Interview


NEW YORK, July 11, 2003 (PRIMEZONE) -- Currently in advanced Phase 3 clinical trials of testing Dexanabinol, a drug used to treat traumatic brain injury (TBI), Pharmos Corporation (NasdaqSC:PARS - News) is poised to tackle a $1 billion market for the product, the company's President and Chief Operating Officer, Gad Riesenfeld told http://www.wallst.net.


The drug is the only TBI treatment that is in an advanced testing phase, Riesenfeld said. Pending FDA approval, Pharmos has expanded their centers for research adding 15 more in the United States in the near future. With 60 medical testing centers worldwide existing already, Dexanabinol has seen expansive testing to date.

Riesenfeld said that once the drug gains FDA approval it will be sold for $5 thousand for a single IV. Currently, he added, there are ``about 2 million brain injuries in the United States annually, and about 150 thousand of those are labeled as severe traumatic brain injuries.'' The potential annual market within the United States is $500 million, and nearly the same in Europe, Riesenfeld said.
The company plans to partner with a larger pharmaceutical company to market their innovation once they gain approval from the FDA, he said.

``By the end of this year, or at the latest, in early 2004, we shall complete the enrollment for the traumatic brain injury study, and we should un-blind the data by late 2004,'' Riesenfeld said.

To hear the entire interview, visit http://www.wallst.net.

[Ca$hmandt]

Pharmos Corporation Reports 2003 Second Quarter Results

Momentum Builds in U.S. Clinical Operations and Cognitive Impairment Trial

ISELIN, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS and Nasdaq Europe: PHRM) today reported financial results for the second quarter and six month periods ended June 30, 2003. During the second quarter, net loss increased to $4,314,119, or $ .07 per share compared to a net loss of $3,351,023, or $ .06 per share in the second quarter 2002. The higher net loss was due primarily to the recording of a derivative charge pursuant to accounting requirements in connection with warrants issued in the Company's March 2003 refinancing. Cash and cash equivalents totaled $20,937,107 at June 30, 2003, which includes net proceeds from a private equity transaction completed in May 2003.

Operating expenses in the second quarter 2003 decreased 2% to $3,238,173 compared to the second quarter 2002, primarily due to decreased selling, general and administrative expenses resulting from a company-wide cost-containment program implemented in the first quarter 2003. Research and development expenses increased 6% to $2,317,564 in the second quarter 2003 compared to the second quarter 2002, resulting from higher costs in clinical operations, primarily the Company's Phase III brain injury trial of dexanabinol in which the number of patients and centers have increased. The higher Phase III clinical operations costs were slightly offset by reduced Phase III-related professional and consulting fees and increased grant funding compared to the same quarter 2002.

"With the development of dexanabinol for traumatic brain injury now at this late stage of clinical testing, we are directing greater attention toward important regulatory undertakings, including the preparation of Fast Track and Orphan Drug submissions to the FDA," said Haim Aviv, Ph.D., Pharmos Chairman and CEO. "Another important area of focus intended to build shareholder value is the broadening of our central nervous system pipeline with our second clinical program, testing dexanabinol's effectiveness in preventing cognitive impairment in patients undergoing coronary artery bypass grafting procedures." Fast Track designation allows for, among other things, accelerated approval of therapeutics meeting an unmet medical need for a serious disease. Orphan Drug status, allowed for drugs intended to treat a condition affecting fewer than 200,000 persons, provides additional benefits, such as strengthened marketing rights.

Approximately 675 of 900 total patients have been enrolled to date in over 70 international centers participating in the Phase III clinical trial of dexanabinol for traumatic brain injury, including 15 centers in the U.S. Data from the study should be available in the second half 2004 . In its Phase IIa trial of dexanabinol for prevention of cognitive impairment, several dozen heart surgery patients have been enrolled to date in four Israeli centers. Up to 200 total heart surgery patients will be enrolled in the exploratory study. Traumatic brain injury and cognitive impairment each represent substantial market opportunities where no current treatments exist.

For the six months ended June 30, 2003, Pharmos reported a net loss of $8,813,324, or $ .14 per share compared to a net loss of $8,319,092, or $ .15 per share for the same period in 2002. The higher net loss is due primarily to the derivative charge in connection with the equity warrants related to the March 2003 refinancing, and to increased research and development costs in the first half 2003 compared to the same period in 2002. Research and development expenses increased 8% to $6,356,629 as a result of higher costs in clinical operations, primarily the Company's Phase III brain injury trial of dexanabinol. The derivative charge and the increase in research and development were partially offset by higher interest income and lower costs in interest expense and selling, general and administrative expenses.

[Ca$hmandt]

:)

NEW YORK, Sept 30 (Reuters) - Pharmos Corp. (NasdaqSC:PARS - News) said on Tuesday that U.S. regulators will review its experimental drug for treating severe traumatic brain injury on an accelerated basis.

The drug, dexanabinol, is designed to treat an often life-threatening condition for which no approved treatments exist. Dexanabinol is designed to help treat the kinds of brain injury seen in automobile accidents and falls among the elderly.

The U.S. Food and Drug Administration (News - Websites) typically grants fast track status to drugs intended to treat serious or life-threatening conditions. It allows companies to submit data in stages, as different parts of clinical trials are completed, rather than waiting to submit all of it at the end.

[Ca$hmandt]

läuft doch erste sahne das teil! :)

Pharmos Corporation to Present at the Rodman & Renshaw Techvest Healthcare Conference


ISELIN, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS; Nasdaq Europe: PHRM) announced today Dr. Haim Aviv, Chairman & CEO, will present to institutional investors and analysts attending the Rodman & Renshaw Techvest Healthcare conference in Boston on Tuesday, October 21, at 3:00 p.m. Eastern Time. Pharmos' presentation will concentrate on dexanabinol, the Company's lead compound under development, currently being tested clinically for traumatic brain injury (Phase III trial) and mild cognitive impairment in cardiac surgery patients (Phase IIa). The presentation will also outline other areas of therapeutic potential held within the Company's rich neurological pipeline.
A simultaneous audio-only webcast of Pharmos' presentation will be available at http://www.wallstreetwebcasting.com/webcast/rrshq/pars/, and will be archived for a limited time after the conference. The slides to the presentation will be available on Pharmos' website at http://www.pharmoscorp.com/.

[Ca$hmandt]

2 Bücher kann ich als gewinn verbuchen! :D ;)

[Ca$hmandt]

Pharmos Corporation Completes $27 Million Equity Offering

ISELIN, N.J., Dec. 19 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS - News) announced today the closing of its previously announced public offering. Pharmos sold 10,500,000 common shares at a price of $2.75 per share. The stock was offered in a firm commitment underwriting pursuant to an existing shelf registration statement. C.E. Unterberg, Towbin and Harris Nesbitt Gerard acted as underwriters for the offering.


The net proceeds of this offering to Pharmos were approximately $27 million. Pharmos intends to use such net proceeds for general corporate purposes, research and product development activities (potentially including the acquisition of new technologies), conducting preclinical studies and clinical trials, and for the equipping of facilities.

[Ca$hmandt]

Pharmos Corporation to Present at the J.M. Dutton Health Sciences Conference

ISELIN, N.J., Jan. 21 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS - News) announced today that its Executive Vice President & Chief Financial Officer, Robert W. Cook, will present at 10:20 am Pacific Time on January 22nd at J.M. Dutton's Health Sciences Conference at the Omni Hotel in San Francisco, California. Mr. Cook will present Pharmos' corporate message to key members of the investment community including portfolio managers, analysts, brokers and investment bankers. The presentation will be webcast live at http://www.friedlandcapitalevents.com/Webcasts.htm and will be available for replay in an archived version at the same location for a limited time.

[Ca$hmandt]

Pharmos Completes Enrollment of Brain Injury Patients in Phase III Study of Dexanabinol

Study Results Expected Around Yearend


ISELIN, N.J., March 15 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS - News) announced today that it has completed patient enrollment in its pivotal Phase III study of dexanabinol for the treatment of severe traumatic brain injury (TBI). The planned recruitment of 860 patients was completed with enrollment of a patient at the University of Virginia neurosurgery unit. A total of 86 trauma centers throughout the U.S., Europe, Israel and Australia participated in the study. The Company expects to unblind the study data and announce initial results near the end of this year.

"Our efforts are now centered on collecting all the relevant data as required by the trial protocol," said Gad Riesenfeld, Ph.D., President and COO.

"I am very satisfied with the quality of the study," said Andrew I.R. Maas, M.D., Director of Neurosurgical Intensive Care, Erasmus University Medical Center, Rotterdam, the Netherlands, Chairman of the European Brain Injury Consortium, and the head of the dexanabinol trial Steering Committee. "We believe that taken together, the study design as reflected in the clinical protocol, the statistical plan, and the dedicated work of the study investigators and the steering committee, are providing the best opportunity for the Company to demonstrate the neuroprotective activity of dexanabinol in TBI patients."

The purpose of the double-blinded, placebo controlled study is to evaluate the efficacy and safety of dexanabinol as a neuroprotectant agent in severe TBI patients. Enrolled patients were given a single dose of 150mg dexanabinol or (placebo) vehicle within six hours after injury and received the standard care normally provided to TBI patients in intensive care units. The primary endpoint for the study will be patient outcome as measured on the Glasgow Outcome Scale - Extended (GOSE) six months after injury.

[Ca$hmandt]

Pharmos Receives Grant from Israel Government

Office of the Chief Scientist Awards US$ 3.1 Million to Fund Dexanabinol Development

REHOVOT, Israel and ISELIN, N.J., April 1 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS - News) today announced it has been awarded a grant of up to US$ 3.1 million by the Office of the Chief Scientist (OCS) of Israel's Ministry of Industry and Trade to help fund the Company's development of dexanabinol. Approximately 93% of the funding is designated for the development of dexanabinol as a treatment for traumatic brain injury (TBI), currently in advanced Phase III clinical testing with patient enrollment completed and results expected by yearend. The remaining portion of the grant will help fund the development of dexanabinol as a preventive agent against cognitive impairment in patients undergoing major heart surgery, in which patient enrollment in a Phase II study is underway. The grant is available through fiscal year 2004 and is paid in direct relationship to actual expenditures made by the Company in the designated programs.

"We are pleased to be awarded this and previous funding from the Office of the Chief Scientist, which will help offset expenses in our clinical development programs as they advance toward completion," said Haim Aviv, Ph.D., Chairman and Chief Executive Officer. "The grant, which is in line with our expectations, is important confirmation of our work with dexanabinol. We appreciate the support from the OCS especially in light of the agency's budgetary constraints."

Prior OCS grants to help fund various research and development projects totaled approximately US$ 10.9 million at December 31, 2003. The Company is required to pay royalties to the OCS ranging from 3% to 5% of product sales, if any, that result from the research activities conducted with such funds, up to the total amount of the grants.

The OCS is largely focused on promoting the growth of commercial research and development in Israel. Its implementation of a 1984 government policy, codified in the Law for the Encouragement of Industrial Research and Development, includes various assistance programs that provide qualifying companies in high-tech industries with incentives to avidly undertake R&D activities. By sharing the risks inherent in high-tech research and development projects, the Israeli government hopes to facilitate expansion of its growing technological infrastructure, a main component of the country's economy.

[Ca$hmandt]

ISELIN, N.J., May 6 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS - News) today reported financial results for the first quarter ended March 31, 2004. Net loss increased to $5,940,801, or $.07 per share compared to a net loss of $4,499,205, or $.08 per share in the 2003 first quarter. Cash and cash equivalents totaled $62,661,578 at March 31, 2004, which includes $16,000,000 in restricted cash reserved for acquisition activity.

Compared to the 2003 first quarter, operating expenses in the 2004 first quarter decreased 11% to $4,488,435. Research and development expenses fell 18% in the 2004 first quarter to $3,300,930, primarily due to lower expenses in connection with the Company's pivotal, Phase III trial of dexanabinol as a treatment for traumatic brain injury (TBI), which expenses in the 2003 first quarter rose as the Company expanded the Phase III trial into the U.S. The Company completed total enrollment of 861 U.S. and international TBI patients in the 2004 first quarter.

The decrease in research and development expenses was partially offset by an increase in general and administrative expenses, which rose to $1,037,711 compared to $852,899 in the 2003 first quarter reflecting higher salaries, professional and insurance fees. The decrease in operating expenses in the 2004 first quarter was offset by an increase in other expenses to $1,452,366 from other income of $564,375 in the 2003 first quarter. Other expenses increased primarily due to the recording of a net credit of $786,000 in the 2003 first quarter pursuant to the financial reporting requirements of the convertible debt with a favorable conversion feature issued by Pharmos in September 2000, the remaining balance of which was retired in the 2003 first quarter.

"Having completed patient enrollment in the pivotal trial of dexanabinol for TBI, we expect to finish the study in the next few months and to know the results toward yearend," said Haim Aviv, Ph.D., Chairman and CEO. "With product development in our first target indication at an advanced stage, we are devoting increased resources to expand clinical operations in other targeted indications, build our pipeline and strengthen our position in the neurological and neuro-inflammatory therapeutic marketplaces."

Pharmos is clinically testing dexanabinol separately in a Phase II study as a preventive agent against post-surgical cognitive impairment in six centers in Israel. Approximately 150 patients undergoing coronary artery bypass grafting (CABG) surgery have been enrolled as of late April 2004. Pharmos will enroll a total of up to 200 CABG patients in the study and expects to have results around yearend. Preclinical studies are focusing on the Company's lead CB2-selective receptor agonist compounds, which have demonstrated efficacy in several animal models for pain and multiple sclerosis. The leading CB2-selective compound is currently undergoing advanced preclinical and toxicological development and is slated for testing in humans within the next twelve months to assess safety and efficacy in treating "opiate refractory" cancer pain.

Gad Riesenfeld, Ph.D., President and COO, and Ray McKee, Ph.D., Vice President, Investor Relations and Corporate Development, will host a conference call to discuss the 2004 first quarter results at 12:00 noon Eastern time on Friday, May 21, 2004. A link to the live webcast of the conference call will be available on the home page of Pharmos' website at www.pharmoscorp.com and will be archived for a limited time afterwards.

[Ca$hmandt]

Pharmos Corporation Reports 2004 Second Quarter Results

Enrollment of CABG Patients Completed in Phase II Cognitive Impairment Clinical Trial


ISELIN, N.J., July 28 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS - News) today reported financial results for the second quarter and six month periods ended June 30, 2004. During the second quarter, net loss was $5,285,301, or $.06 per share compared to a net loss of $4,314,119, or $.07 per share in the 2003 second quarter. The increase in net loss was due primarily to a 35% rise in operating costs to $4,359,918 in the 2004 second quarter, driven largely by higher administrative expenses, including a non- cash charge of approximately $400,000. Cash and cash equivalents totaled $54,608,206 at June 30, 2004, including $13,521,538 in restricted cash.

General and administrative expenses rose to $1,712,634 in the 2004 second quarter from $752,032 in the 2003 second quarter due to increased activities with consultants and professional fees along with higher salaries and benefits from additional headcount, and a non-cash charge of approximately $400,000 for a modification to a former employee stock option agreement. The 2004 second quarter also saw higher expenditures due to the scale up of dexanabinol synthesis and to increased accounting and legal services fees, including Sarbanes-Oxley compliance-related services.

Net research and development expenses increased 8% in the 2004 second quarter to $2,497,008 from $2,317,564 in the 2003 second quarter, with increased earlier stage research and development expenses and lower grant funding partially offset by a decrease in clinical trial expenses. In its leading clinical operation, the pivotal Phase III trial of dexanabinol for traumatic brain injury, enrollment of 861 total patients was completed in the first quarter 2004. In mid-July 2004, Pharmos completed enrollment of 202 patients undergoing coronary artery bypass grafting (CABG) surgery in a separate, Phase II trial of dexanabinol as a preventive agent against post- surgical cognitive impairment.

"With enrollment completed in both of our clinical trials, research and development operations are now focused on patient follow up, data management and quality assurance before unblinding the results around yearend," said Haim Aviv, Ph.D., Chairman and CEO. "We have also increased our efforts in building our pipeline for other targeted neuroinflammatory indications by expanding preclinical research of compounds from our CB2 receptor agonist family. These new products represent large therapeutic markets which support a higher valuation and product diversification" The Company's leading CB2-selective compound, which has demonstrated efficacy in several animal models for pain and multiple sclerosis, is currently undergoing advanced preclinical development in preparation for human testing as a pain therapeutic.

For the six months ended June 30, 2004, Pharmos reported a net loss of $11,226,102, or $ .13 per share compared to a net loss of $8,813,324, or $ .14 per share for the same period in 2003, primarily due to an increase in other expenses, in particular interest expense in connection with the convertible securities issued in September 2003. Research and development expenses narrowed to $5,797,938 from $6,356,629 in the same period in 2003, due to a decrease in clinical trial costs and increased grant funds in the 2004 first quarter. General and administrative expenses increased to $2,750,345 from $1,604,931 in the 2003 same period due to higher professional fees, salaries and insurance costs and the non-cash charge mentioned above. The higher professional fees in 2004 are attributed to increased accounting fees, Sarbanes-Oxley compliance-related expenses and earlier timing of the Company's annual shareholder meeting. Other expenses increased in the six month period ended June 30, 2004 to $2,377,749 from $511,571 in the same period in 2003 primarily due to increased interest expense from the issuance of the convertible debt in September 2003. The increased interest expense was partially offset by lower derivative expense and its respective market to market adjustment.

Pharmos management will host a conference call to discuss the 2004 second quarter results at 11:00 a.m. eastern time on Thursday, July 29, 2004. A link to the live webcast of the conference call will be available on the home page of Pharmos' website at http://www.pharmoscorp.com and will be archived for a limited time afterwards.

[moony]

Kapitalerhöhung wurde erfolgreich abgeschlossen.
Es wurden 5.58 Millionen Aktien zu einem Kurs von 3 $ emittiert.

[Ca$hmandt]

daher ging der kurs auch 10% runter! :rolleyes:

[moony]

Dexanabinol enttäuschte in einer Studie der Phase II. Es wurde dabei Patienten verabreicht, die einer Herzoperation unterzogen wurden. Es konnte allerdings nur teilweise kognitive Schäden verhindern.

Wichtiger werden allerdings die Ergebnisse einer Phase-III-Studie erachtet, in der erhoben werden soll, ob Dexanabinol Unfallopfer vor traumatischen Hirnschädigungen bewahren kann. Diese soll bis zum Jahresende abgeschlossen sein. Im Erfolgsfall erwarten Analysten ein Umsatzpotential von bis zu 1 Milliarde Dollar jährlich.

[Ca$hmandt]

dem kurs tuts keinen abbruch, nur ein leichtes minus! :)

[Ca$hmandt]

dafür gabs heute was auf die birne: -12,7% auf 3,22! :eek:

die meldung dazu:

Neural Cell Therapy Programs Reviewed by NeuroInvestment

RYE, NH--(MARKET WIRE)--Dec 2, 2004 -- NI Research today announced the release of the December issue of NeuroInvestment, overviewing the development of cell-based therapeutics for the treatment of neurological disorders. Cell therapy and gene therapy are the final frontiers of regenerative medicine, and regenerative medicine is a long-term hope for addressing many of the disorders of aging that are taking an increasing toll in the developed world. Much has been written about the highly politicized climate within which cell therapies are trying to mature in the US, it is an unfortunate situation where science is subservient to political and religious agendas. In spite of this, and in spite of the fact that several cell therapy companies have gone out of business for lack of financing and/or merit, there are a number of survivors, a few of which are in the clinic, or are approaching it. While we still consider this field to be far from maturity, there are discrete areas where it may provide clinically useful solutions within the next five to ten years. StemCells (NasdaqSC:STEM - News) is approaching the clinic with a treatment for the rare disorder Batten's Disease, while Ceregene and Neurologix are now in the clinic for Alzheimer's and Parkinson's respectively, with gene therapy programs that have sprung from a cell therapy genesis. Geron is preparing its ES cells for a trial next year in spinal cord injury, and Schering/Titan are in the midst of a Phase II trial for Parkinson's. All of this is despite the fact that there is as yet no consensus on what type of cells (fetal, embryonic, adult stem cells) along with what type of cell handling, will be optimal for which disorders. This review assesses the current state of the art, along with the companies who are focused upon it.
The December issue also comments on Biogen-Idec and Elan's Antegren and its FDA approval; Merck's current status; and Phase II data that has recently been reported by Pharmos (NasdaqSC:PARS - News), as well as the critical, pending Phase III data from its highly anticipated trial in traumatic brain injury. :eek:

[moony]

Enttäuschende Ergebnisse von Dexanabinol (Phase-III-Studie) zur Behandlung von schweren traumatischen Kopfverletzungen.

http://bigcharts.marketwatch.com/charts/big.chart?symb=PARS&compidx=aaaaa%3A0&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=2&size=2&state=8&sid=3748&style=320&time=9&freq=1&nosettings=1&rand=9850&mocktick=1&rand=7309

[Ca$hmandt]

tja und wie gehts nun weiter? günstiger einstieg oder vergessen?

[moony]

Ich würde eher sagen, dass es sich langfristig um günstige Einstiegskurse handelt.

http://bigcharts.marketwatch.com/charts/big.chart?symb=pars&compidx=aaaaa%3A0&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=2&size=2&state=8&sid=3748&style=320&time=13&freq=2&nosettings=1&rand=7307&mocktick=1&rand=2431

Leider kenne ich die Pipeline von Pharmos nicht und beschäftige mich auch wenig mit dem Wert. :rolleyes:

Heute scheint aber etwas zu gehen.
Bei Überschreiten der 1.25$ auf Schlusskursbasis kann man sich mal eine kleine Position sichern.

http://bigcharts.marketwatch.com/charts/big.chart?symb=pars&compidx=aaaaa%3A0&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=2&size=2&state=8&sid=3748&style=320&time=3&freq=7&nosettings=1&rand=8268&mocktick=1&rand=9082

Ca$hi, falls Du noch drin bist, Nachkaufen ist eher eine schlechte Strategie.
Muß aber jeder selber wissen. ;)